You're signed outSign in or to get full access.
About
Luna Ji, MD, is a Principal at RTW Investments, LP, where she leads investments and strategic initiatives in the biotechnology and pharmaceutical sectors. Her role centers on identifying, evaluating, and managing investments in innovative life sciences companies, focusing on preclinical and clinical-stage therapeutics and technologies.
Previously, Luna Ji served as Director of Business Development and Licensing at Merck and was Vice President at Lilly Asia Ventures, where she specialized in cross-border investments, deal sourcing, and partnership development within the life sciences arena. Her deep sector expertise covers biopharma venture capital, business development, and licensing, with a particular emphasis on global biotech innovations and emerging therapeutics.
Dr. Ji holds a Doctor of Medicine degree in Clinical Medicine from Peking University, equipping her with a strong foundation in medical science and translational research. Over her decade-long career, she has contributed to the successful advancement and financing of breakthrough healthcare companies, significantly shaping investment trends in global biotechnology.
Career History
| Organization | Role | Date Range | Details |
|---|---|---|---|
| RTW Investments, LP | Principal | Apr 2024 to Present | — |
| Merck | Director, BD and L | Aug 2020 to May 2024 | Lead of Greater China of Search and Evaluation in the Pacific BD&L Hub of Merck Sharp & Dohme (“MSD”, also known as Merck & Co. in the US) since 2020. Covers life sciences and biotech opportunities le... |
| Lilly Asia Ventures 礼来亚洲基金 | Vice President | Jan 2016 to Aug 2020 | Led multiple equity investments in both China and US across different therapeutic areas, including Jacobio, SciNeuro, Alector, among others, and served as a Director of the Board on these portfolio co... |
| Novartis | Clinical Lead | Jun 2014 to Jan 2016 | Manage compound profile and development strategy new compound in Therapeutic Area.
Work closely with cross-function team on CTA, CTW, NDA submission, as well as provide input from medical aspect in th... |
| The Janssen Pharmaceutical Companies of Johnson & Johnson | Therapeutic Area Physician | Jun 2012 to May 2014 | Study Responsible Physician for phase III International Multi-center Clinical Trials in Clinical Development in Solid tumor, MSL for immunology biologics. |
| Peking University People's Hospital | Resident | Apr 2010 to Jun 2012 | Resident/Medical Student in Department of Dermatology |
Education
Peking University
Doctor of Medicine (M.D.), Clinical Medicine
2004 — 2012
Shenzhen Middle School
1998 — 2004
Others at RTW Investments, LP (14)
| Name | Role | Location |
|---|---|---|
 | Partner | New York, NY , United States |
 | Research Associate | Scarsdale, NY , United States |
 | Head Trader | New York, NY , United States |
N Naveen Yalamanchi | Partner | New York, NY , United States |
R Robert Rapaport | Research Analyst | New York, NY , United States |
 | Senior Analyst | New York, NY , United States |
 | Research Analyst | NY , United States |
J Jeffrey Wang | Research Analyst | New York, NY , United States |
 | Partner | New York, NY , United States |
L Lauren Lee | Research Analyst | New York, NY , United States |
Similar Fund Managers
| Name | Role | Fund | Location |
|---|---|---|---|
A Andrey Belov | Research Analyst | Cramer Rosenthal Mcglynn LLC | Stamford, CT , United States |
B Brian Harvey | Equity Portfolio Manager | Cramer Rosenthal Mcglynn LLC | United States |
